May. 7 at 8:15 PM
$AMRX Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of
$0.20 up 400.00% YoY
• Reported revenue of
$722.52M up 3.90% YoY
• Amneal Pharmaceuticals Inc. raised its full year 2026 guidance, now projecting adjusted EBITDA of
$740 million to
$770 million and adjusted diluted EPS of
$0.95 to
$1.05, reflecting strong performance and momentum.
